Previous 10 | Next 10 |
SAN DIEGO , June 4, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced today the acceptance of an invitation from the Global Coaliti...
SAN DIEGO , June 1, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that two posters updating results from the company's tw...
DelMar Pharmaceuticals (NASDAQ: DMPI ): Q3 GAAP EPS of -$0.17 misses by $0.01 . More news on: DelMar Pharmaceuticals, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
SAN DIEGO , May 13, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced its financial results for the three and nine months ended March 3...
SAN DIEGO , May 5, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced today it has enrolled 22 patients in the adjuvant arm of the C...
SAN DIEGO , March 26, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced that it has received a listing extension from the Staf...
Nano cap DelMar Pharmaceuticals ( DMPI +4.2% ) is up on below-average volume on the heels of its announcement that the last participant has been enrolled and has begun treatment in a China-based single-arm, open-label, 30-subject Phase 2 clinical trial evaluating lead drug VAL-083...
SAN DIEGO , Feb. 19, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced it has enrolled and begun dosing the final patient in its on...
DelMar Pharmaceuticals (NASDAQ: DMPI ): Q2 GAAP EPS of -$0.15 beats by $0.10 . More news on: DelMar Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN DIEGO , Feb. 13, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced its financial results for the three and six months ended Decembe...
News, Short Squeeze, Breakout and More Instantly...
DelMar Pharmaceuticals Company Name:
DMPI Stock Symbol:
NASDAQ Market:
SAN DIEGO , Aug. 18, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company") announced today that it has entered into definitive agreements with investors providing for the sale and issuance of up to 19,587 shares of its Series C Convert...
SAN DIEGO , Aug. 17, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company") announced today that all proposals related to the proposed merger between DelMar and Adgero were approved by DelMar's stockholders at a special meeting held on August 14...
SAN DIEGO , July 17, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies announced today that it will be conducting a conference call to discuss...